[
  {
    "title": "华兰股份：新冠疫苗用胶塞客户有康希诺、神州细胞等",
    "href": "http://stock.jrj.com.cn/2022/12/29194837247421.shtml",
    "datetime": "2022-12-29 19:48:15",
    "code": "688520"
  },
  {
    "title": "神州细胞坚持自主研发不到五年投29亿 谢良志1.5亿增持及参与定增加码持股",
    "href": "http://stock.jrj.com.cn/2022/12/06115937191431.shtml",
    "datetime": "2022-12-06 11:59:32",
    "code": "688520"
  },
  {
    "title": "两天内四家宣布：新冠肺炎疫苗被纳入紧急使用！千亿市值“疫苗第一股”应声大跌",
    "href": "http://stock.jrj.com.cn/2022/12/06003037190544.shtml",
    "datetime": "2022-12-06 00:30:19",
    "code": "688520"
  },
  {
    "title": "A股异动 | 神州细胞涨12% 控股子公司新冠疫苗SCTV01C被纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2022/12/05092937187563.shtml",
    "datetime": "2022-12-05 09:29:56",
    "code": "688520"
  },
  {
    "title": "神州细胞：控股子公司新冠疫苗SCTV01C被纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2022/12/04160137186875.shtml",
    "datetime": "2022-12-04 16:01:41",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：新冠疫苗SCTV01C被纳入紧急使用、预计不会对本年度业绩产生重大影响",
    "href": "http://stock.jrj.com.cn/2022/12/04153937186845.shtml",
    "datetime": "2022-12-04 15:39:26",
    "code": "688520"
  },
  {
    "title": "神州细胞新冠mRNA疫苗三期临床与辉瑞疫苗头对头取得积极结果，疫苗商业化曙光在前？",
    "href": "http://stock.jrj.com.cn/2022/11/16140937143263.shtml",
    "datetime": "2022-11-16 14:09:22",
    "code": "688520"
  },
  {
    "title": "A股异动丨神州细胞大幅高开近7% 披露新冠疫苗临床试验III期研究进展",
    "href": "http://stock.jrj.com.cn/2022/11/16092837142468.shtml",
    "datetime": "2022-11-16 09:28:19",
    "code": "688520"
  },
  {
    "title": "晚间公告全知道：神州细胞披露新冠疫苗临床试验III期研究进展、现代投资获湖南轨道举牌",
    "href": "http://stock.jrj.com.cn/2022/11/15215037141867.shtml",
    "datetime": "2022-11-15 21:50:51",
    "code": "688520"
  },
  {
    "title": "神州细胞：披露新冠疫苗临床试验III期研究进展",
    "href": "http://stock.jrj.com.cn/2022/11/15205037141718.shtml",
    "datetime": "2022-11-15 20:50:47",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：拟使用不超1亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/11/15200137141536.shtml",
    "datetime": "2022-11-15 20:01:09",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：神州细胞工程拟设立澳大利亚全资子公司、从事医药研发及产销等业务",
    "href": "http://stock.jrj.com.cn/2022/11/15195937141493.shtml",
    "datetime": "2022-11-15 19:59:48",
    "code": "688520"
  },
  {
    "title": "A股异动 | 神州细胞大涨逾13% 新冠疫苗SCTV01E获得国内药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/11/11094337130056.shtml",
    "datetime": "2022-11-11 09:43:57",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：新冠疫苗SCTV01E获得国内药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/11/10215237129221.shtml",
    "datetime": "2022-11-10 21:52:02",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：神州细胞工程通过高新技术企业认定",
    "href": "http://stock.jrj.com.cn/2022/11/08170637120808.shtml",
    "datetime": "2022-11-08 17:06:27",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)定增结果出炉：财通基金、诺德基金、UBS AG及赵建平等等参投",
    "href": "http://stock.jrj.com.cn/2022/11/07210237118466.shtml",
    "datetime": "2022-11-07 21:02:22",
    "code": "688520"
  },
  {
    "title": "从三季度预告出发，来看神州细胞-U（688520.SH）迈向长期价值进阶之路",
    "href": "http://stock.jrj.com.cn/2022/10/25185837082698.shtml",
    "datetime": "2022-10-25 18:58:11",
    "code": "688520"
  },
  {
    "title": "神州细胞：预计前三季度净亏损约4亿元 同比减亏",
    "href": "http://stock.jrj.com.cn/2022/10/23191537076113.shtml",
    "datetime": "2022-10-23 19:15:51",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：前三季度预计实现营收6.5亿元、同比增长6373.77%",
    "href": "http://stock.jrj.com.cn/2022/10/23161537075695.shtml",
    "datetime": "2022-10-23 16:15:08",
    "code": "688520"
  },
  {
    "title": "神州细胞：控股子公司新冠疫苗披露临床试验免疫持久性分析结果",
    "href": "http://stock.jrj.com.cn/2022/10/19175937067551.shtml",
    "datetime": "2022-10-19 17:59:05",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)披露新冠疫苗SCTV01C临床试验免疫持久性分析结果",
    "href": "http://stock.jrj.com.cn/2022/10/19174737067525.shtml",
    "datetime": "2022-10-19 17:47:54",
    "code": "688520"
  },
  {
    "title": "A股异动 | 神州细胞涨8% 新冠疫苗SCTV01C、SCTV01E和灭活苗对照组间的安全性高度相似",
    "href": "http://stock.jrj.com.cn/2022/10/18102337063029.shtml",
    "datetime": "2022-10-18 10:23:33",
    "code": "688520"
  },
  {
    "title": "神州细胞：新冠疫苗SCTV01E和SCTV01C临床试验III期取得积极结果",
    "href": "http://stock.jrj.com.cn/2022/10/17183637061304.shtml",
    "datetime": "2022-10-17 18:36:06",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：神州细胞工程的瑞帕妥单抗注射液(商品名：安平希)获批上市",
    "href": "http://stock.jrj.com.cn/2022/08/31000736955324.shtml",
    "datetime": "2022-08-31 00:07:24",
    "code": "688520"
  },
  {
    "title": "神州细胞今年上半年归母净亏损为2.50亿元",
    "href": "http://stock.jrj.com.cn/2022/08/24112036929597.shtml",
    "datetime": "2022-08-24 11:20:19",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：拟使用不超2.6亿元暂时闲置募资进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/08/23155936926244.shtml",
    "datetime": "2022-08-23 15:59:08",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)上半年净亏损2.5亿元",
    "href": "http://stock.jrj.com.cn/2022/08/23155736926247.shtml",
    "datetime": "2022-08-23 15:57:43",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：实控人谢良志及控股股东拉萨爱力克已累计增持56.40万股",
    "href": "http://stock.jrj.com.cn/2022/07/05173736784002.shtml",
    "datetime": "2022-07-05 17:37:01",
    "code": "688520"
  },
  {
    "title": "神州细胞：子公司重组新冠疫苗I/II期临床研究取得积极结果",
    "href": "http://stock.jrj.com.cn/2022/06/22182236750413.shtml",
    "datetime": "2022-06-22 18:22:03",
    "code": "688520"
  },
  {
    "title": "神州细胞：控股股东拟以5000万元-1亿元增持公司股份",
    "href": "http://stock.jrj.com.cn/2022/06/20165436743156.shtml",
    "datetime": "2022-06-20 16:54:52",
    "code": "688520"
  },
  {
    "title": "神州细胞：控股子公司2价新冠疫苗SCTV01C国内临床试验I期研究期中分析结果出炉",
    "href": "http://stock.jrj.com.cn/2022/06/17104736737116.shtml",
    "datetime": "2022-06-17 10:47:20",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：神州细胞工程2价新冠疫苗SCTV01C国内临床试验I期研究期中分析取得积极结果",
    "href": "http://stock.jrj.com.cn/2022/06/16172436735069.shtml",
    "datetime": "2022-06-16 17:24:04",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520)首次公开发行战略配售限售股于2022年6月22日上市流通",
    "href": "http://stock.jrj.com.cn/2022/06/15090536729807.shtml",
    "datetime": "2022-06-15 09:05:30",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：200万股限售股将于6月22日解禁上市",
    "href": "http://stock.jrj.com.cn/2022/06/14182936728481.shtml",
    "datetime": "2022-06-14 18:29:26",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：控股子公司拟变更药品生产许可证",
    "href": "http://stock.jrj.com.cn/2022/06/06190636706673.shtml",
    "datetime": "2022-06-06 19:06:03",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：子公司产品SCTV01E获得约旦II期临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/05/24163536674330.shtml",
    "datetime": "2022-05-24 16:35:18",
    "code": "688520"
  },
  {
    "title": "神州细胞选举谢良志为董事长 2021年度公司亏损8.67亿",
    "href": "http://stock.jrj.com.cn/2022/05/17231136656908.shtml",
    "datetime": "2022-05-17 23:11:05",
    "code": "688520"
  },
  {
    "title": "神州细胞2022年第一季度亏损1.43亿同比亏损减少 产品销量稳步提升",
    "href": "http://stock.jrj.com.cn/2022/05/04123236555280.shtml",
    "datetime": "2022-05-04 12:32:40",
    "code": "688520"
  },
  {
    "title": "神州细胞2021年亏损8.67亿同比亏损增加 董事长谢良志薪酬17.54万",
    "href": "http://stock.jrj.com.cn/2022/04/27223136487026.shtml",
    "datetime": "2022-04-27 22:31:12",
    "code": "688520"
  },
  {
    "title": "神州细胞披露2021年年报 实现营收1.34亿元",
    "href": "http://stock.jrj.com.cn/2022/04/27111636482547.shtml",
    "datetime": "2022-04-27 11:16:16",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520)：董事会、监事会换届选举",
    "href": "http://stock.jrj.com.cn/2022/04/27085736481067.shtml",
    "datetime": "2022-04-27 08:57:01",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：神州细胞工程的贝伐珠单抗注射液注册申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/04/21174336420119.shtml",
    "datetime": "2022-04-21 17:43:42",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：2033.57万股限售股3月28日上市流通",
    "href": "http://stock.jrj.com.cn/2022/03/18171034845716.shtml",
    "datetime": "2022-03-18 17:10:59",
    "code": "688520"
  },
  {
    "title": "神州细胞2021年亏损8.67亿同比亏损增加 市场销售费用同步增加",
    "href": "http://stock.jrj.com.cn/2022/02/24201334453205.shtml",
    "datetime": "2022-02-24 20:13:00",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)2021年度预亏8.5亿-8.8亿元",
    "href": "http://stock.jrj.com.cn/2022/01/28210734248694.shtml",
    "datetime": "2022-01-28 21:07:24",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：重组人凝血因子VIII的新增儿童适应症补充申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/01/07155334133566.shtml",
    "datetime": "2022-01-07 15:53:26",
    "code": "688520"
  },
  {
    "title": "神州细胞：阿达木单抗注射液药品注册申请获受理",
    "href": "http://stock.jrj.com.cn/2021/12/15203934020984.shtml",
    "datetime": "2021-12-15 20:39:13",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：子公司产品阿达木单抗注射液药品注册申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/12/15182534020399.shtml",
    "datetime": "2021-12-15 18:25:38",
    "code": "688520"
  },
  {
    "title": "【晚间公告抢先看】中国中免暂缓本次H股发行上市的进程、神州细胞子公司新冠中和抗体药物获临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/12/03214533961800.shtml",
    "datetime": "2021-12-03 21:45:15",
    "code": "688520"
  },
  {
    "title": "神州细胞子公司新冠中和抗体药物获临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/12/03192933961271.shtml",
    "datetime": "2021-12-03 19:29:57",
    "code": "688520"
  },
  {
    "title": "神州细胞：控股子公司新冠中和抗体药物获药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/12/03191433961238.shtml",
    "datetime": "2021-12-03 19:14:07",
    "code": "688520"
  },
  {
    "title": "神州细胞：子公司新冠中和抗体药物获临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/12/03183833961018.shtml",
    "datetime": "2021-12-03 18:38:08",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：子公司新冠中和抗体药物获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/12/03183333961006.shtml",
    "datetime": "2021-12-03 18:33:10",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：向特定对象发行股票申请获中证监同意注册批复",
    "href": "http://stock.jrj.com.cn/2021/11/23162533909662.shtml",
    "datetime": "2021-11-23 16:25:58",
    "code": "688520"
  },
  {
    "title": "A股异动 | 神州细胞(688520.SH)涨近5% 重组新冠疫苗产品临床试验申请获批",
    "href": "http://stock.jrj.com.cn/2021/11/15113733853545.shtml",
    "datetime": "2021-11-15 11:37:32",
    "code": "688520"
  },
  {
    "title": "“神药”在手，神州细胞的止血时刻何时到来？",
    "href": "http://stock.jrj.com.cn/2021/11/15082133852570.shtml",
    "datetime": "2021-11-15 08:21:40",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：重组新冠病毒Alpha+Beta变异株S三聚体蛋白疫苗获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/11/12205933842636.shtml",
    "datetime": "2021-11-12 20:59:56",
    "code": "688520"
  },
  {
    "title": "亏损扩大！神州细胞前三季度净亏损6.61亿元",
    "href": "http://stock.jrj.com.cn/2021/10/29104733775891.shtml",
    "datetime": "2021-10-29 10:47:55",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：第三季度净亏损2.24亿元",
    "href": "http://stock.jrj.com.cn/2021/10/27195233763739.shtml",
    "datetime": "2021-10-27 19:52:16",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)半年度净亏损4.37亿元",
    "href": "http://stock.jrj.com.cn/2021/08/25192333318194.shtml",
    "datetime": "2021-08-25 19:23:05",
    "code": "688520"
  },
  {
    "title": "神州细胞2021年半年度亏损4.37亿元 同比亏损增加",
    "href": "http://stock.jrj.com.cn/2021/08/25183833317910.shtml",
    "datetime": "2021-08-25 18:38:06",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：定增募资额拟由不超39.61亿元调减至不超22.40亿元",
    "href": "http://stock.jrj.com.cn/2021/08/16204733262423.shtml",
    "datetime": "2021-08-16 20:47:37",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：向特定对象发行股票申请 收到第三轮审核问询函",
    "href": "http://stock.jrj.com.cn/2021/08/10192633233210.shtml",
    "datetime": "2021-08-10 19:26:43",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：子公司的注射用重组人凝血因子VIII获批上市",
    "href": "http://stock.jrj.com.cn/2021/07/23173633140951.shtml",
    "datetime": "2021-07-23 17:36:01",
    "code": "688520"
  },
  {
    "title": "神州细胞回复向特定对象发行股票申请文件二轮问询：针对前募资金、融资规模等说明",
    "href": "http://stock.jrj.com.cn/2021/06/16104332939470.shtml",
    "datetime": "2021-06-16 10:43:07",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：2109.24万股限售股将于6月22日上市流通",
    "href": "http://stock.jrj.com.cn/2021/06/11171932912127.shtml",
    "datetime": "2021-06-11 17:19:39",
    "code": "688520"
  },
  {
    "title": "神州细胞第一季度亏损1.92亿同比亏损增大 研发费用增长",
    "href": "http://stock.jrj.com.cn/2021/04/16164332387021.shtml",
    "datetime": "2021-04-16 16:43:39",
    "code": "688520"
  },
  {
    "title": "神州细胞：目前公司各项目存不存在断掉资金链风险",
    "href": "http://stock.jrj.com.cn/2021/04/15151032379402.shtml",
    "datetime": "2021-04-15 15:10:40",
    "code": "688520"
  },
  {
    "title": "神州细胞2020年亏损7.13亿元：董事长谢良志薪酬14.93万元",
    "href": "http://stock.jrj.com.cn/2021/04/15135332378950.shtml",
    "datetime": "2021-04-15 13:53:20",
    "code": "688520"
  },
  {
    "title": "研发持续“烧钱”，市值蒸发上百亿 神州细胞发年报当日收问询函",
    "href": "http://stock.jrj.com.cn/2021/04/15123132378633.shtml",
    "datetime": "2021-04-15 12:31:38",
    "code": "688520"
  },
  {
    "title": "尚未实现盈利！神州细胞去年继续亏损营收下滑超八成",
    "href": "http://stock.jrj.com.cn/2021/04/15102132377859.shtml",
    "datetime": "2021-04-15 10:21:03",
    "code": "688520"
  },
  {
    "title": "神州细胞去年营收下滑87.56% 净亏损7.13亿元",
    "href": "http://stock.jrj.com.cn/2021/04/15070932376551.shtml",
    "datetime": "2021-04-15 07:09:00",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：2020年度亏损收窄 净亏损7.13亿元",
    "href": "http://stock.jrj.com.cn/2021/04/14200832373430.shtml",
    "datetime": "2021-04-14 20:08:37",
    "code": "688520"
  },
  {
    "title": "神州细胞：卡南吉抗癌新药CM082在2020年已上市即将成为贝达药业的现金奶牛",
    "href": "http://stock.jrj.com.cn/2021/04/14101932369835.shtml",
    "datetime": "2021-04-14 10:19:46",
    "code": "688520"
  },
  {
    "title": "神州细胞：神州细胞工程在研项目临床试验补充申请获批准",
    "href": "http://stock.jrj.com.cn/2021/04/13090932362658.shtml",
    "datetime": "2021-04-13 09:09:39",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：控股子公司药物临床试验补充申请获批",
    "href": "http://stock.jrj.com.cn/2021/04/12164932358240.shtml",
    "datetime": "2021-04-12 16:49:09",
    "code": "688520"
  },
  {
    "title": "神州细胞：“SCT-I10A联合化疗一线治疗复发性和/或转移性头颈部鳞癌”项目目前仍在III期临床研究",
    "href": "http://stock.jrj.com.cn/2021/04/07150232324990.shtml",
    "datetime": "2021-04-07 15:02:42",
    "code": "688520"
  },
  {
    "title": "神州细胞：公司代号为SCTA01的新冠中和抗体的项目仍在进行",
    "href": "http://stock.jrj.com.cn/2021/04/07150132324989.shtml",
    "datetime": "2021-04-07 15:01:20",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)定增申请获上交所受理",
    "href": "http://stock.jrj.com.cn/2021/03/29170332241907.shtml",
    "datetime": "2021-03-29 17:03:12",
    "code": "688520"
  },
  {
    "title": "神州细胞：中国抗VEGF单抗生物类似药市场预计将在2030年达到99亿元",
    "href": "http://stock.jrj.com.cn/2021/03/12082032113270.shtml",
    "datetime": "2021-03-12 08:20:47",
    "code": "688520"
  },
  {
    "title": "科创板公司神州细胞2020年营收仅32.82万 网友：还不如养100头猪",
    "href": "http://stock.jrj.com.cn/kcb/2021/02/23210632014329.shtml",
    "datetime": "2021-02-23 21:06:12",
    "code": "688520"
  },
  {
    "title": "神州细胞2020年度亏损7.13亿同比亏损减少 首次公开发行股票募集资金到账",
    "href": "http://stock.jrj.com.cn/2021/02/23200332014082.shtml",
    "datetime": "2021-02-23 20:03:53",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)业绩快报：2020年度亏损收窄 净亏损7.13亿元",
    "href": "http://stock.jrj.com.cn/2021/02/23175832013327.shtml",
    "datetime": "2021-02-23 17:58:54",
    "code": "688520"
  },
  {
    "title": "神州细胞2020年预计亏损约6.95亿-7.25亿 研发费用持续增大",
    "href": "http://stock.jrj.com.cn/2021/01/27225231794144.shtml",
    "datetime": "2021-01-27 22:52:31",
    "code": "688520"
  },
  {
    "title": "神州细胞拟定增39.61亿元，控股股东拉萨爱力克认购不超1亿元",
    "href": "http://stock.jrj.com.cn/2021/01/25095231762356.shtml",
    "datetime": "2021-01-25 09:52:57",
    "code": "688520"
  },
  {
    "title": "神州细胞：拟定增募资不超39.6亿元 用于新药研发等项目",
    "href": "http://stock.jrj.com.cn/2021/01/24174831751970.shtml",
    "datetime": "2021-01-24 17:48:08",
    "code": "688520"
  },
  {
    "title": "神州细胞五年投超17亿研发 专注顽固性疾病五大领域",
    "href": "http://stock.jrj.com.cn/2021/01/07074631645516.shtml",
    "datetime": "2021-01-07 07:46:11",
    "code": "688520"
  },
  {
    "title": "神州细胞跌10% 汇祥资产旗下私募为第八大流通股东",
    "href": "http://stock.jrj.com.cn/2020/12/16174931503376.shtml",
    "datetime": "2020-12-16 17:49:00",
    "code": "688520"
  },
  {
    "title": "神州细胞：首次公开发行网下配售限售股上市流通公告",
    "href": "http://stock.jrj.com.cn/2020/12/15001031489805.shtml",
    "datetime": "2020-12-15 00:10:00",
    "code": "688520"
  },
  {
    "title": "神州细胞(688520.SH)：260.26万股限售股12月22日解禁",
    "href": "http://stock.jrj.com.cn/2020/12/14163231487504.shtml",
    "datetime": "2020-12-14 16:32:11",
    "code": "688520"
  },
  {
    "title": "神州细胞：2020年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/10/28001031145360.shtml",
    "datetime": "2020-10-28 00:10:00",
    "code": "688520"
  },
  {
    "title": "神州细胞前三季度亏损5.15亿同比亏损减少 贷款利息支出相应增加",
    "href": "http://stock.jrj.com.cn/2020/10/27221831144888.shtml",
    "datetime": "2020-10-27 22:18:06",
    "code": "688520"
  },
  {
    "title": "[神州细胞]神州细胞首次亮相第十二届WFH中国血友病大会",
    "href": "http://stock.jrj.com.cn/2020/09/29000030861366.shtml",
    "datetime": "2020-09-29 00:00:00",
    "code": "688520"
  },
  {
    "title": "神州细胞：公司将根据发展进度不断补充和更新研发团队的配置 完善自主建设技术平台和工艺平台配置",
    "href": "http://stock.jrj.com.cn/2020/09/15094830753288.shtml",
    "datetime": "2020-09-15 09:48:56",
    "code": "688520"
  },
  {
    "title": "神州细胞：公司的产品线均为通用型生产线",
    "href": "http://stock.jrj.com.cn/2020/09/14144530747613.shtml",
    "datetime": "2020-09-14 14:45:05",
    "code": "688520"
  },
  {
    "title": "神州细胞上半年又亏损3.4亿营收仅16万 中金公司保荐",
    "href": "http://stock.jrj.com.cn/2020/08/28164330614922.shtml",
    "datetime": "2020-08-28 16:43:00",
    "code": "688520"
  },
  {
    "title": "神州细胞2020年上半年亏损3.4亿万亏损减少 租赁成本减少",
    "href": "http://stock.jrj.com.cn/2020/08/28111730612543.shtml",
    "datetime": "2020-08-28 11:17:14",
    "code": "688520"
  },
  {
    "title": "神州细胞：公司为自主研发企业 目前未有产品上市销售",
    "href": "http://stock.jrj.com.cn/2020/08/19124130537532.shtml",
    "datetime": "2020-08-19 12:41:36",
    "code": "688520"
  },
  {
    "title": "神州细胞副总经理盖文琳辞职 因个人原因",
    "href": "http://stock.jrj.com.cn/2020/07/09213130194642.shtml",
    "datetime": "2020-07-09 21:31:38",
    "code": "688520"
  },
  {
    "title": "科创板神州细胞午后涨停",
    "href": "http://stock.jrj.com.cn/2020/07/01143630110649.shtml",
    "datetime": "2020-07-01 14:36:40",
    "code": "688520"
  },
  {
    "title": "医保局发文将核酸检测等纳入医保 神州细胞登陆科创板首日涨幅超180% | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/06/22180929989953.shtml",
    "datetime": "2020-06-22 18:09:54",
    "code": "688520"
  },
  {
    "title": "【兑奖啦】神州细胞网上申购中签号出炉 中签号28600个",
    "href": "http://stock.jrj.com.cn/ipo/2020/06/10190629891724.shtml",
    "datetime": "2020-06-10 19:06:20",
    "code": "688520"
  },
  {
    "title": "神州细胞：网上发行最终中签率为0.04277027％",
    "href": "http://stock.jrj.com.cn/ipo/2020/06/09192329882741.shtml",
    "datetime": "2020-06-09 19:23:16",
    "code": "688520"
  },
  {
    "title": "今日新股申购：帝科股份、神州细胞",
    "href": "http://stock.jrj.com.cn/2020/06/09092629878347.shtml",
    "datetime": "2020-06-09 09:26:00",
    "code": "688520"
  },
  {
    "title": "科创板新股神州细胞6月9日申购宝典",
    "href": "http://stock.jrj.com.cn/kcb/2020/06/08141629871584.shtml",
    "datetime": "2020-06-08 14:16:08",
    "code": "688520"
  },
  {
    "title": "神州细胞：将登陆科创板公开发行5000万股",
    "href": "http://stock.jrj.com.cn/2020/06/01160729815692.shtml",
    "datetime": "2020-06-01 16:07:00",
    "code": "688520"
  },
  {
    "title": "神州细胞：研发投入大 生产工艺存风险",
    "href": "http://stock.jrj.com.cn/2020/04/07073729221766.shtml",
    "datetime": "2020-04-07 07:37:00",
    "code": "688520"
  },
  {
    "title": "神州细胞过会：今年科创板过会第11家 中金公司过2单",
    "href": "http://stock.jrj.com.cn/2020/04/01140229168281.shtml",
    "datetime": "2020-04-01 14:02:00",
    "code": "688520"
  },
  {
    "title": "上交所：孚能科技、神州细胞科创板首发过会",
    "href": "http://stock.jrj.com.cn/2020/03/31183929159734.shtml",
    "datetime": "2020-03-31 18:39:00",
    "code": "688520"
  },
  {
    "title": "复旦张江、孚能科技、神州细胞3月31日科创板上会",
    "href": "http://stock.jrj.com.cn/2020/03/23090629080341.shtml",
    "datetime": "2020-03-23 09:06:00",
    "code": "688520"
  },
  {
    "title": "科创板上市委：孚能科技、神州细胞首发3月31日上会",
    "href": "http://stock.jrj.com.cn/2020/03/20192229071396.shtml",
    "datetime": "2020-03-20 19:22:00",
    "code": "688520"
  },
  {
    "title": "神州细胞：有望降低甲型血友病治疗价格 争取让产品进入医保目录",
    "href": "http://stock.jrj.com.cn/2020/01/06194028632768.shtml",
    "datetime": "2020-01-06 19:40:11",
    "code": "688520"
  },
  {
    "title": "神州细胞回复上交所首次问询函",
    "href": "http://stock.jrj.com.cn/kcb/2019/12/03055228480620.shtml",
    "datetime": "2019-12-03 05:52:12",
    "code": "688520"
  },
  {
    "title": "前沿生物、君实生物、神州细胞科创板中止审核",
    "href": "http://stock.jrj.com.cn/2019/10/31202528335016.shtml",
    "datetime": "2019-10-31 20:25:00",
    "code": "688520"
  },
  {
    "title": "神州细胞财务数据混乱 硬件条件或很难符合上市标准",
    "href": "http://stock.jrj.com.cn/kcb/2019/09/29092428195867.shtml",
    "datetime": "2019-09-29 09:24:02",
    "code": "688520"
  },
  {
    "title": "上交所受理孚能科技、神州细胞上市申请 扣非净利润均为负",
    "href": "http://stock.jrj.com.cn/2019/09/18000028142340.shtml",
    "datetime": "2019-09-18 00:00:17",
    "code": "688520"
  },
  {
    "title": "估值逾110亿 生物制药研发公司神州细胞科创板IPO申请获受理",
    "href": "http://stock.jrj.com.cn/kcb/2019/09/17081228138335.shtml",
    "datetime": "2019-09-17 08:12:22",
    "code": "688520"
  },
  {
    "title": "上交所科创板受理孚能科技、神州细胞上市申请",
    "href": "http://stock.jrj.com.cn/2019/09/16171428135961.shtml",
    "datetime": "2019-09-16 17:14:00",
    "code": "688520"
  }
]